Picture of Genocea Biosciences logo

GNCAQ — Genocea Biosciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Genocea Biosciences Inc expected to post a loss of 18  cents a share - Earnings Preview

* Genocea Biosciences Inc  GNCA.OQ   GNCA.O  is expected
to show a
rise in quarterly revenue when it reports  results on April 27
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
revenue of $566.67 thousand, according to the mean estimate from
3 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Genocea Biosciences
Inc
is for a loss of 18 cents per share. For the same quarter last
year, the company reported a loss of 17 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Genocea
Biosciences Inc is $6​, above​ its last closing price of $0.42.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021              -0.20      -0.19     Beat    5
 Sep. 30 2021  -0.20       -0.20      -0.05     Beat    74.7
 Jun. 30 2021  -0.18       -0.18      -0.06     Beat    67​
 Mar. 31 2021  -0.20       -0.20      -0.17     Beat    14.1
 ​​Dec.        -0.21       -0.21      -0.23     Missed  -10.6
 31 2020                                                
 Sep. 30 2020  -0.25       -0.24      -0.08     Beat    66.9​
 Jun. 30 2020  -0.41       -0.40      -0.39     Beat    3.7
 Mar. 31 2020  -0.34       -0.35      -0.46     Missed  -30.7
 This summary was machine generated April 25 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Genocea Biosciences

See all news